ES2177293T3 - Composicion que comprende acido beta-hidroxi-beta-metilbutirico y como un minimo un aminoacido. - Google Patents

Composicion que comprende acido beta-hidroxi-beta-metilbutirico y como un minimo un aminoacido.

Info

Publication number
ES2177293T3
ES2177293T3 ES99930567T ES99930567T ES2177293T3 ES 2177293 T3 ES2177293 T3 ES 2177293T3 ES 99930567 T ES99930567 T ES 99930567T ES 99930567 T ES99930567 T ES 99930567T ES 2177293 T3 ES2177293 T3 ES 2177293T3
Authority
ES
Spain
Prior art keywords
beta
composition
methylbutiric
hidroxi
minimum
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES99930567T
Other languages
English (en)
Inventor
Steven L Nissen
Naji M Abumrad
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Iowa State University Research Foundation Inc ISURF
Original Assignee
Iowa State University Research Foundation Inc ISURF
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22292520&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2177293(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Iowa State University Research Foundation Inc ISURF filed Critical Iowa State University Research Foundation Inc ISURF
Application granted granted Critical
Publication of ES2177293T3 publication Critical patent/ES2177293T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Nutrition Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

Una composición que comprende ácido -hidroxi-- metilbutírico (HMB), L-glutamina y L-arginina.
ES99930567T 1998-06-23 1999-06-23 Composicion que comprende acido beta-hidroxi-beta-metilbutirico y como un minimo un aminoacido. Expired - Lifetime ES2177293T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/102,941 US6031000A (en) 1998-06-23 1998-06-23 Composition comprising β-hydroxy-β-methylbutyric acid and at least one amino acid and methods of use

Publications (1)

Publication Number Publication Date
ES2177293T3 true ES2177293T3 (es) 2002-12-01

Family

ID=22292520

Family Applications (1)

Application Number Title Priority Date Filing Date
ES99930567T Expired - Lifetime ES2177293T3 (es) 1998-06-23 1999-06-23 Composicion que comprende acido beta-hidroxi-beta-metilbutirico y como un minimo un aminoacido.

Country Status (12)

Country Link
US (1) US6031000A (es)
EP (1) EP1089726B1 (es)
JP (2) JP5064609B2 (es)
AU (1) AU756353B2 (es)
CA (1) CA2334761C (es)
DE (1) DE69901396T2 (es)
DK (1) DK1089726T3 (es)
ES (1) ES2177293T3 (es)
NO (2) NO329914B1 (es)
NZ (1) NZ508395A (es)
PL (1) PL195623B1 (es)
WO (1) WO1999066917A2 (es)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3362350B2 (ja) * 1997-10-16 2003-01-07 味の素株式会社 反芻動物の肥育方法
US20040220266A1 (en) * 2002-09-09 2004-11-04 Wiley David B. Composition and method for enhancing the bioavailability of calcium and magnesium in dietary supplements and food additives
US20040106678A1 (en) * 2002-09-17 2004-06-03 Dobbins Thomas A Compositions for the parenteral administration of calcium and magnesium
US6812249B2 (en) * 2003-03-04 2004-11-02 Sal Abraham Process for preparing a 3-hydroxy-3-methylbutyrate amino acid salt and method of use
US20050215640A1 (en) * 2004-03-26 2005-09-29 Baxter Jeffrey H HMB compositions and uses thereof
WO2007056176A2 (en) * 2005-11-03 2007-05-18 Southwest Immunology, Inc. Compositions for preventing and reducing delayed onset muscle soreness
ES2363442T3 (es) * 2005-11-30 2011-08-04 Nestec S.A. Combinación que comprende al menos una aminoácido y un inhibidor de pkr para utilizar en el tratamiento de la pérdida de masa muscular.
WO2007075605A2 (en) * 2005-12-19 2007-07-05 Abbott Laboratories Use of beta-hydroxy-beta-methylbutyrate to modulate the imbalance in type and type 2 cytokine production
US7754693B2 (en) * 2006-02-16 2010-07-13 Young Hee Ko Composition and method for the efficacious and safe administration of halopyruvate for the treatment of cancer
US8324175B2 (en) 2006-02-16 2012-12-04 Young Hee Ko Compositions and methods for the treatment of cancer
PT2381784T (pt) * 2008-12-09 2018-10-30 Metabolic Tech Inc Intervenção nutricional para melhorar função e força muscular
US9539224B2 (en) 2008-12-09 2017-01-10 Metabolic Technologies, Inc. Nutritional intervention for improving muscular function and strength
US11173167B2 (en) 2008-12-09 2021-11-16 Metabolic Technologies, Inc. Nutritional intervention for improving muscular function and strength
US9707241B2 (en) 2008-12-09 2017-07-18 Metabolic Technologies, Inc. Nutritional intervention for improving muscular function and strength
US9770424B2 (en) * 2008-12-09 2017-09-26 Metabolic Technologies, Inc. Nutritional intervention for improving muscular function and strength
US9259430B2 (en) 2008-12-09 2016-02-16 Metabolic Technologies, Inc. Nutritional intervention for improving muscular function and strength
PL2391363T3 (pl) * 2009-01-29 2017-03-31 Young Hee Ko Kompozycje i sposoby do leczenia raka
EP2289555A1 (en) * 2009-08-24 2011-03-02 OrgaNext Research B.V. Method of treating frailty
PT2512236T (pt) * 2009-12-18 2016-12-29 Metabolic Tech Inc Método aperfeiçoado de administração de beta-hidroxi-beta-metilbutirato (hmb)
US9693577B2 (en) 2010-01-29 2017-07-04 Abbott Laboratories Method of preparing a nutritional powder comprising spray dried HMB
SG182808A1 (en) 2010-01-29 2012-09-27 Abbott Lab Aseptically packaged nutritional liquids comprising hmb
MX2012008785A (es) 2010-01-29 2012-08-17 Abbott Lab Emulsiones nutricionales que comprenden beta-hidroxi-beta-metilbut irato (hmb) de calcio.
TWI526161B (zh) 2010-06-10 2016-03-21 亞培公司 包含鈣ｈｍｂ及可溶性蛋白質之實質上透明營養液
EP3466418A1 (en) 2011-07-15 2019-04-10 NuSirt Sciences, Inc. Compositions and methods for modulating metabolic pathways
WO2013067485A1 (en) 2011-11-03 2013-05-10 University Of Florida Research Foundation, Inc. Nutritional supplement for weight management
EP3437649A1 (en) * 2011-11-21 2019-02-06 Emmaus Medical Inc. Methods and compositions for the treatment of diabetes and related symptoms
EP2802322B1 (en) 2012-01-11 2018-02-28 Abbott Laboratories Combination of beta-hydroxy-beta-methylbutyrate, arginine and glutamine for use in treating diabetic ulcers
US9198454B2 (en) 2012-03-08 2015-12-01 Nusirt Sciences, Inc. Compositions, methods, and kits for regulating energy metabolism
WO2014040067A1 (en) 2012-09-10 2014-03-13 Metabolic Technologies, Inc. Composition of hmb and atp and methods of use
WO2014047493A1 (en) * 2012-09-21 2014-03-27 Abbott Laboratories Nutritional compositions including calcium beta-hydroxy-beta-methylbutyrate and protein
SG11201502205SA (en) 2012-09-21 2015-04-29 Abbott Lab Nutritional compositions including calcium beta-hydroxy-beta-methylbutyrate, protein and low levels of electrolytes
SG11201503774PA (en) 2012-11-13 2015-06-29 Nusirt Sciences Inc Compositions and methods for increasing energy metabolism
SG11201507390SA (en) * 2013-03-14 2015-10-29 Abbott Lab Treatment of insulin resistance associated with prolonged physical inactivity
CN105228627B (zh) 2013-03-15 2018-07-13 纽斯尔特科学公司 亮氨酸和烟酸降低脂质水平
US20150057350A1 (en) * 2013-08-23 2015-02-26 Abbott Laboratories Fibrosis biomarkers and methods of using same
MX2016011063A (es) 2014-02-27 2016-11-30 Nusirt Sciences Inc Composiciones y metodos para la reduccion o prevencion de esteatosis hepatica.
MX2017015418A (es) * 2015-06-01 2018-08-24 Metabolic Tech Inc Composiciones y metodos de uso de beta-hidroxi-beta-metilbutirato (hmb) para reducir grasa corporal.
JP7114458B2 (ja) 2015-09-16 2022-08-08 メタボリック・テクノロジーズ，インコーポレーテッド 軟組織外傷からの回復を増強するためのβ－ヒドロキシ－β－メチルブチレート（ＨＭＢ）の組成物および使用方法
US12208073B2 (en) 2015-09-16 2025-01-28 Metabolic Technologies, LLC Compositions and methods of use of beta-hydroxy-beta-methylbutyrate (HMB) for enhancing recovery from soft tissue trauma
KR20180088809A (ko) 2015-11-19 2018-08-07 가부시키가이샤 오츠카 세이야쿠 코죠 3-히드록시이소발레르산의 1가 양이온염의 결정 및 그 결정의 제조 방법
BR112018014920A2 (en) 2016-01-21 2018-12-18 Metabolic Technologies, Inc. methods of modulating autophagy, treating or reducing the likelihood of onset of an autophagy-mediated condition, treating, inhibiting, reducing, decreasing, or preventing an age-related disorder, modulating the expression or activity of at least one factor transcription, treatment, prevention, reduction, inhibition or reduction of a pathological condition attributable to a state of nutrient excess, promoting longevity by modulating autophagy, increasing the length of time a mammal can lead a lifestyle active without suffering from conditions associated with aging and extending the health of a mammal.
US12533346B2 (en) 2016-04-19 2026-01-27 Axcess Global Sciences, Llc Administration of berberine metabolites
US12496283B2 (en) 2016-04-19 2025-12-16 Axcess Global Sciences, Llc Administration of R-beta-hydroxybutyrate and related compounds in humans
US12599579B2 (en) 2016-04-19 2026-04-14 Axcess Global Sciences, Llc Compositions and compounds containing ketone bodies and/or ketone body precursors and one or more amino acids
US12109182B2 (en) 2016-04-19 2024-10-08 Axcess Global Sciences, Llc Administration of R-beta-hydroxybutyrate and related compounds in humans
US12622889B2 (en) 2016-04-19 2026-05-12 Axcess Global Sciences, Llc S-β-hydroxybutyrate esters for improving metabolic function
US12521378B2 (en) 2016-04-19 2026-01-13 Axcess Global Sciences, Llc Administration of R-beta-hydroxybutyrate salt blend and related compounds in humans
US20230346721A1 (en) 2018-04-18 2023-11-02 Axcess Global Sciences, Llc Beta-hydroxybutyric acid compositions and methods for delivery of ketone bodies
US12329734B2 (en) 2017-12-19 2025-06-17 Axcess Global Sciences, Llc Use of S-beta-hydroxybutyrate compounds for induction and maintenance of flow
US11026929B2 (en) 2016-04-19 2021-06-08 Keto Patent Group, Inc. Administration of berberine metabolites
SG11201809211QA (en) * 2016-04-19 2018-11-29 Keto Patent Group Inc Administration of butyrate, beta-hydroxybutyrate, and related compounds in humans
EP3476825A4 (en) 2016-06-24 2020-02-26 Kyowa Hakko Bio Co., Ltd. CRYSTAL OF BETA-HYDROXY-BETA-METHYLBUTTERIC ACID-AMINO ACID SALT AND PRODUCTION METHOD THEREFOR
PL3528801T3 (pl) 2016-10-21 2025-02-03 Metabolic Technologies, LLC Kompozycje i sposoby zastosowania beta-hydroksy-beta-metylomaślanu (hmb) i probiotyków
JOP20190146A1 (ar) * 2016-12-19 2019-06-18 Axcella Health Inc تركيبات حمض أميني وطرق لمعالجة أمراض الكبد
US12171735B2 (en) 2017-04-19 2024-12-24 Axcess Global Sciences, Llc Administration of butyrate, beta-hydroxybutyrate, cannabidiol, and related compounds in humans
SG11202001142VA (en) 2017-08-14 2020-03-30 Axcella Health Inc Amino acid compositions for the treatment of liver disease
EP3735236A4 (en) * 2018-01-05 2021-10-20 Texas Tech University Office Of Research Commercialization COMPOSITIONS AND METHODS OF USE OF BETA-HYDROXY-BETA-METHYL BUTYRATE (HMB) IN ASSOCIATION WITH INTERMITTENT FASTING
US10596136B2 (en) 2018-06-20 2020-03-24 Axcella Health Inc. Compositions and methods for the treatment of fat infiltration in muscle
CN117545498A (zh) * 2021-05-14 2024-02-09 荷兰医疗食品有限公司 用于保持肌肉量的营养组合物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5157022A (en) * 1989-11-22 1992-10-20 Adrian Barbul Method for reducing blood cholesterol using arginine
US5028440A (en) * 1990-01-30 1991-07-02 Iowa State University Research Foundation, Inc. Method of raising meat producing animals to increase lean tissue development
US4992470A (en) * 1990-02-08 1991-02-12 Iowa State University Research Foundation, Inc. Method of enhancing immune response of mammals
CA2142314C (en) * 1992-09-16 1999-06-01 Steven L. Nissen Method of reducing blood levels of total cholesterol and low-density lipoprotein cholesterol
US5348979A (en) * 1992-12-23 1994-09-20 Iowa State University Research Foundation Inc. Method of promoting nitrogen retention in humans
AU6102994A (en) * 1993-02-11 1994-08-29 Iowa State University Research Foundation Inc. Method of enhancing nutritional value of colostrum and first milk of pregnant mammals
US5726146A (en) * 1994-12-06 1998-03-10 Natural Supplement Association, Incorporated Non-steroidal, anabolic dietary supplement and method to increase lean mass without linked increase fat mass
US5756469A (en) * 1996-07-26 1998-05-26 Beale; Paxton K. Composition of pyruvate and anti-cortisol compounds and method for increasing protein concentration in a mammal
DE29707308U1 (de) * 1997-04-23 1997-06-26 Kunz, Armin, 66450 Bexbach Präparat zur Muskelerhaltung bzw. zur Förderung des Muskelaufbaus

Also Published As

Publication number Publication date
NO20101440L (no) 2001-02-20
JP2012102118A (ja) 2012-05-31
NO329914B1 (no) 2011-01-24
DK1089726T3 (da) 2002-07-22
NO332374B1 (no) 2012-09-10
PL195623B1 (pl) 2007-10-31
CA2334761C (en) 2009-04-28
WO1999066917A2 (en) 1999-12-29
NO20006633D0 (no) 2000-12-22
PL344589A1 (en) 2001-11-05
NO20006633L (no) 2001-02-20
EP1089726A2 (en) 2001-04-11
JP2002518440A (ja) 2002-06-25
EP1089726B1 (en) 2002-05-02
US6031000A (en) 2000-02-29
DE69901396D1 (de) 2002-06-06
DE69901396T2 (de) 2002-08-29
JP5690261B2 (ja) 2015-03-25
AU756353B2 (en) 2003-01-09
CA2334761A1 (en) 1999-12-29
AU4708099A (en) 2000-01-10
NZ508395A (en) 2003-09-26
WO1999066917A3 (en) 2000-04-20
JP5064609B2 (ja) 2012-10-31

Similar Documents

Publication Publication Date Title
ATE289640T1 (de) Amidofunktionelle aminopolydiorganosiloxane
MXPA05006629A (es) Formas de dosificacion que contienen un inhibidor de bomba de protones, un nsaid y un amortiguador.
DE59913840D1 (de) Effektoren von Dipeptidylpeptidase IV
ATE264863T1 (de) 28-epirapaloge
PL360092A1 (en) Structures and compositions increasing the stability of peroxide actives
NO990857D0 (no) Fosfinsyreamider som matriks-metallprotease-inhibitorer
UY27346A1 (es) Composiciones farmaccuticas que contienen conjuntos de polemero y frrmaco.
BR9906070A (pt) Benzamidas substituìdas
JO2212B1 (en) 4-PDE inhibitors for ethan substituted with three Ariel groups
SG168401A1 (en) Catalyst and use thereof
MXPA03010801A (es) Material polimerico que contiene un acido latente.
ES2181168T3 (es) Mezclas solidas a base de sulfonilureas y adyuvantes.
CY1107297T1 (el) Συνθεση με μυκητοκτονο δραση με βαση αλας καλιου του φωσφορωδους οξεος (potassium acid phosphite)
ES2184398T3 (es) Mezclas herbicidas a base de aclonifeno y de clomazona.
DE60107457D1 (de) Vorvernetzungshemmende zusammensetzung
EA200200091A1 (ru) Содержащая амброксол пастилка
MX9704683A (es) Inhibidores de la escualeno sintetasa.
CY1108791T1 (el) Φυτοενδυναμωτικο μεσον
EP1073449A4 (en) AMINO ACID AMIDINOHYDRAZONES, ALCOXYGUANIDINES AND AMINOGUANIDINES FOR USE AS ENZYME PROTEASE INHIBITORS
ATE238791T1 (de) Verwendung von 2-methyl-thiazolidin-2,4- dicarbonsäure als mukolytikum
ATE242763T1 (de) Methoximinophenylessigsäureamide
AP2000001945A0 (en) Leishmania cysteine proteinases.
ATE270113T1 (de) Zusammenstellungen zur verbesserten wundheilung
AR041373A1 (es) Composicion y metodo para blanquear un sustrato
ES2186971T3 (es) Composicion herbicida.